5.13
Sana Biotechnology Inc stock is traded at $5.13, with a volume of 6.56M.
It is down -0.19% in the last 24 hours and up +72.73% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
See More
Previous Close:
$5.14
Open:
$5.25
24h Volume:
6.56M
Relative Volume:
1.46
Market Cap:
$1.16B
Revenue:
-
Net Income/Loss:
$-283.26M
P/E Ratio:
-3.4898
EPS:
-1.47
Net Cash Flow:
$-273.61M
1W Performance:
+15.28%
1M Performance:
+72.73%
6M Performance:
+51.78%
1Y Performance:
-16.18%
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Compare SANA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SANA
Sana Biotechnology Inc
|
5.13 | 1.16B | 0 | -283.26M | -273.61M | -1.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-03-25 | Resumed | Morgan Stanley | Overweight |
Mar-18-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
Mar-14-25 | Initiated | Jefferies | Buy |
Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
Nov-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Jun-26-24 | Initiated | Rodman & Renshaw | Buy |
Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
Sep-05-23 | Initiated | Citigroup | Buy |
Aug-14-23 | Initiated | TD Cowen | Market Perform |
May-02-23 | Initiated | H.C. Wainwright | Neutral |
Mar-01-21 | Initiated | BofA Securities | Buy |
Mar-01-21 | Initiated | Goldman | Neutral |
Mar-01-21 | Initiated | JP Morgan | Neutral |
Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
What analysts say about Sana Biotechnology Inc. stockExplosive portfolio gains - Autocar Professional
Citi Maintained a Buy Rating on Sana Biotechnology (SANA) - MSN
Sana Biotechnology Inc. Stock Analysis and ForecastHigh-velocity capital appreciation - jammulinksnews.com
Is Sana Biotechnology Inc. a good long term investmentFree Stock Chart Pattern Guide - Autocar Professional
11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey
Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results - MSN
Commit To Purchase Sana Biotechnology At $2.50, Earn 28% Using Options - Nasdaq
What drives Sana Biotechnology Inc. stock priceMassive profits - jammulinksnews.com
Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors - GlobeNewswire Inc.
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes - Benzinga
Sana Biotechnology, Inc. (SANA) Secures an Overweight Rating from Morgan Stanley - MSN
Sana Biotechnology: A Stem Cell Breakthrough at the Crossroads of Risk and Reward - AInvest
Sana Biotechnology (SANA) Soars 4.11% on Positive Diabetes Data - AInvest
Sana Reports Promising Diabetes Cell Therapy Data at ADA Meeting - MSN
Sana Biotechnology’s SWOT analysis: innovative cell therapy stock faces challenges By Investing.com - Investing.com South Africa
Sana Biotechnology’s SWOT analysis: innovative cell therapy stock faces challenges - Investing.com
Sana Biotechnology's 9% Spike: Technical Signals and Peer Dynamics Drive Unusual Intraday Rally - AInvest
Sana Biotechnology (SANA.O) Surges 9% Amid Technical Bullish Signal: What’s Driving the Move? - AInvest
Sana Biotechnology's 9% Surge: Technical Bullishness or Biotech Momentum? - AInvest
Sana Biotechnology's 9% Surge: Technical Bullish Signal or Sector Shift? - AInvest
Sana Biotechnology’s 9% Surge: Technical Catalysts and Peer Dynamics - AInvest
Sana Biotechnology's 9% Surge: Technicals or a Hidden Catalyst? - AInvest
Sana Biotechnology's 9% Spike: A Technical Catalyst Amid Mixed Biotech Sentiment - AInvest
Sana Biotechnology's 9% Surge: Technical Catalysts and Market Dynamics - AInvest
Morgan Stanley Assigns Overweight Rating to Sana Biotechnology with $12 Price Target - AInvest
Sana Biotechnology assumed with an Overweight at Morgan Stanley - TipRanks
Top 10 CRISPR Stocks to Buy Now - Insider Monkey
Sana Biotechnology, Inc.(NasdaqGS: SANA) added to Russell 3000E Value Index - MarketScreener
Sana Biotechnology (SANA) Receives a Buy from Citizens JMP - The Globe and Mail
BofA Remains Bullish on Sana Biotechnology (SANA) - MSN
Sana Biotechnology's HIP-Engineered Cell Therapy: A Diabetes Cure With Multi-Bagger Potential? - AInvest
SANA Stock on the Rise: A Promising Investment - investchronicle.com
Investigation announced for long-term Investors in shares - openPR.com
Pallas Capital Advisors LLC Makes New $29,000 Investment in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology (NASDAQ:SANA) versus Mosaic ImmunoEngineering (OTCMKTS:CPMV) Critical Analysis - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 25,383 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Lead Plaintiff Appointed in Sana Biotechnology Class Action — Here’s How You Can Recover Your Losses - TradingView
Paysign Leads Our Trio Of Penny Stock Highlights - simplywall.st
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sana Biotechnology Inc Stock (SANA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Cassidy Bernard J | EVP & General Counsel |
Mar 07 '25 |
Option Exercise |
0.00 |
11,041 |
0 |
115,823 |
Harr Steve | President & CEO |
Mar 07 '25 |
Option Exercise |
0.00 |
50,000 |
0 |
7,889,750 |
Wyrick Susan D. | See Remarks |
Mar 02 '25 |
Option Exercise |
0.00 |
1,525 |
0 |
155,471 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):